Proparacaine hydrochloride

An irreversible local anesthetic; inhibits pain sensations that is believed to act as an antagonist on voltage-gated sodium channels.Pain Approved (In Vitro) :Proparacaine Hydrochloride (>588.93 μM; 4-28 hours) has a dose- and time-dependent cytotoxicity to HCS cells at concentrations in vitro.Proparacaine Hydrochloride (294.47-18.85 mM; 4-12 hours) can induce apoptosis of HCS cells .Proparacaine Hydrochloride (4.71 mM; 4-12 hours) induces G1 phase arrest, plasma membrane permeability elevation, phosphatidylserine externalization, DNA fragmentation, chromatin condensation, and apoptotic body formation of HCS cells.Proparacaine Hydrochloride induces caspase-2, -3 and -9 activation, and mitochondrial transmembrane potential disruption.Proparacaine Hydrochloride (4.71 mM; 4-12 hours) downregulates and upregulates the expression of Bcl-xL and Bax, respectively, and remarkably upregulates cytoplasmic cytochrome C and apoptosis inducing factor. (In Vivo) :Proparacaine Hydrochloride (75 μg/30 μL; intranasal administration; for 7 days) significantly decreases nasal symptoms, number of eosinophils, goblet cells, and mast cells in the lamina propria of the nasal mucosa.

5875-06-9

Proxymetacaine hydrochloride

Pharmacology & Drug Discovery

>98% (HPLC)

10 mM in DMSO

CCCOC1=C (C=C (C=C1) C (=O) OCCN (CC) CC) N.Cl

C16H27ClN2O3

330.8502

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.